Table 2.

Characteristics of the IgG4-RD patients with malignancies (n = 20)^*

Patient	Sex	Age at malignancy diagnosis, years	Age at IgG4-RD onset, years	IgG4-RD organ involvement	Malignancy site	Malignancy treatment
1	M	72	82	RPF	Colon	Surgery, chemotherapy
2	M	63, 30	69	AIP, biliary	Prostate, testicle	Surgery
3	M	66	71	ENT, thyroid, lung, aorta	Prostate	Surgery
4	F	69	71	Orbit, parotid, submandibular, skin	Breast	Surgery, radiation
5	M	76	78	Sclerosing mediastinitis, LAD, thyroid, ENT	Prostate	Radiation
6	M	39	61	ENT	Rectal	Surgery, radiation, chemotherapy
7	F	25	34	LAD, orbit	Cervix	Surgery
8	M	54	57	RPF	Prostate	Surgery
9	M	13	32	Aorta	Lymphoma	Chemotherapy
10	M	51	65	LAD, aorta	Prostate	Surgery
11	M	74	79	Parotid, biliary	Lung	Surgery, radiation
12	M	44	51	Parotid, submandibular, LAD	Leukemia	Surgery, chemotherapy
13	M	67	69	Aorta, RPF	Prostate	Radiation
14	F	47	48	Kidney, biliary, pancreas	Breast	Surgery, chemotherapy
15	M	57	61	RPF	Lung	Surgery, chemotherapy
16	M	46	52	Aorta, kidney, heart	Lymphoma	Chemotherapy
17	F	67	69	Parotid, submandibular, LAD	Lymphoma	Chemotherapy
18	M	34	47	Orbital, parotid, submandibular, pancreas	Lymphoma	Chemotherapy
19	M	57	61	Orbital, aorta, pancreas	Prostate	Surgery
20	M	32	39	ENT	Testicle	Surgery

^*IgG4-RD = IgG4-related disease; RPF = retroperitoneal fibrosis; AIP = autoimmune pancreatitis; ENT = ear, nose, throat; LAD = lymphadenopathy.